Investors Sue Corcept Therapeutics Over Alleged Misconduct

Robbins LLP files class action lawsuit on behalf of shareholders who purchased Corcept stock.

Published on Feb. 21, 2026

Got story updates? Submit your updates here. ›

A class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) on behalf of all investors who purchased or acquired the company's common stock between February 21, 2026 and the present. The lawsuit alleges that Corcept made false and misleading statements about its drug relacorilant, which is approaching regulatory approval.

Why it matters

Corcept Therapeutics is a pharmaceutical company focused on developing drugs to treat severe metabolic, oncologic, and psychiatric disorders. The class action lawsuit alleges that the company misled investors about the prospects of its lead drug candidate, relacorilant, potentially impacting shareholder value.

The details

The lawsuit, filed by law firm Robbins LLP, claims that Corcept made false and misleading statements about the development and regulatory approval prospects of relacorilant. Relacorilant is Corcept's lead drug candidate and is approaching approval. The lawsuit alleges that the company failed to disclose material information that could impact the drug's commercial viability.

  • The class action lawsuit was filed on February 21, 2026.

The players

Corcept Therapeutics Inc.

A pharmaceutical company focused on developing drugs to treat severe metabolic, oncologic, and psychiatric disorders.

Robbins LLP

A law firm that filed the class action lawsuit on behalf of Corcept Therapeutics shareholders.

Got photos? Submit your photos here. ›

What’s next

The judge will determine whether to certify the class action lawsuit in the coming months.

The takeaway

This lawsuit highlights the importance of pharmaceutical companies providing accurate and transparent information to investors about the development and regulatory prospects of their drug candidates.